Market revenue in 2023 | USD 17.9 million |
Market revenue in 2030 | USD 54.2 million |
Growth rate | 17.1% (CAGR from 2023 to 2030) |
Largest segment | Pneumococcal conjugate vaccine |
Fastest growing segment | Pneumococcal Conjugate Vaccine |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Walvax Biotechnology, Beijing Minhai Biotechnology Co. |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 92.74% in 2023. Horizon Databook has segmented the Argentina pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
In Argentina, the pneumococcal vaccine market has seen significant growth in recent years. The government has been actively promoting vaccination programs to combat pneumococcal diseases such as pneumonia and meningitis, especially among vulnerable populations like children and the elderly.
One of the key players in the Argentine pneumococcal vaccine market is Pfizer, which offers the Prevenar 13 vaccine. This vaccine has been widely used and trusted by healthcare professionals and parents due to its effectiveness in preventing pneumococcal infections.
However, Pfizer faces competition from other vaccine manufacturers, both domestic and international, who offer alternative pneumococcal vaccines in the Argentine market. These companies provide consumers with a variety of options to choose from based on factors such as cost, availability, and efficacy.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina pneumococcal vaccine market, including forecasts for subscribers. This country databook contains high-level insights into Argentina pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account